TapewireFind a company

person · Reporting owner

Gerngross Tillman U.

Disclosed activity across 3 companies

Tapewire entity
112281
SEC CIK
0001722061

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Invivyd, Inc.ADGI · Entity 721Director · Chief Executive Officer · 10% ownerJanuary 30, 2022February 01, 2022
X4 Pharmaceuticals, IncASNS · Entity 5638DirectorJune 05, 2018June 07, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Invivyd, Inc.

Report date January 30, 2022 · Filed February 01, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2032-01-29Direct175,000 Reported balance After 2022-01-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-01-30 · Grant · Acquired 175,000 · Balance 175,000

F1: This option vests in equal monthly installments over a four-year period measured from one month following January 30, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests in equal monthly installments over a four-year period measured from one month following January 30, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.

X4 Pharmaceuticals, Inc

Report date June 05, 2018 · Filed June 07, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.99 · Expires 2028-06-04Direct10,000 Reported balance After 2018-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-06-05 · Grant · Acquired 10,000 · Balance 10,000

F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Alector, Inc.

Report date June 14, 2023 · Filed June 15, 2023

Section 16 reporting ended · disclosed 2023-06-15. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,644,319 Reported balance After 2023-06-14 transaction · row 1
1 source row

Row 1 · 2023-06-14 · Grant · Acquired 26,250 · Balance 2,644,319

F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the date of the Issuer's next annual meeting of stockholders.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.71 · Expires 2033-06-14Direct12,360 Reported balance After 2023-06-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2023-06-14 · Grant · Acquired 12,360 · Balance 12,360

F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 14, 2023, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the date of the Issuer's next annual meeting of stockholders.

F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 14, 2023, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 14, 2023 Filed Jun 15, 2023 16:04 UTC Alector, Inc. ALEC · Entity 6051 GrantStock Option (right to buy) · Derivative 12,360 $0.00 Strike: $7.71 $0.00
Disclosure

SEC source: 0000950170-23-028275 · ownership.xml · derivative · entry 2

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,360

Underlying: Common Stock · 12,360 shares

Expires 2033-06-14

F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 14, 2023, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders.

Read SEC document
June 14, 2023 Filed Jun 15, 2023 16:04 UTC Alector, Inc. ALEC · Entity 6051 GrantCommon Stock 26,250 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-028275 · ownership.xml · nonDerivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,644,319

F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
June 16, 2022 Filed Jun 21, 2022 19:22 UTC Alector, Inc. ALEC · Entity 6051 GrantStock Option (right to buy) · Derivative 18,918 $0.00 Strike: $8.07 $0.00
Disclosure

SEC source: 0001209191-22-038538 · doc4.xml · derivative · entry 2

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,918

Underlying: Common Stock · 18,918 shares

Expires 2032-06-16

F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 16, 2022, or if earlier, the date of the Issuer's next annual meeting of stockholders.

Read SEC document
June 16, 2022 Filed Jun 21, 2022 19:22 UTC Alector, Inc. ALEC · Entity 6051 GrantCommon Stock 9,459 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-038538 · doc4.xml · nonDerivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,618,069

F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 16, 2023 or (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
January 30, 2022 Filed Feb 1, 2022 18:14 UTC Invivyd, Inc. ADGI · Entity 721 GrantStock Option (Right to Buy) · Derivative 175,000 $0.00 Strike: $6.78 $0.00
Disclosure

SEC source: 0001209191-22-006022 · doc4.xml · derivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2032-01-29

F1 · derivative.exercise_date: This option vests in equal monthly installments over a four-year period measured from one month following January 30, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.

Read SEC document
August 10, 2021 Filed Aug 12, 2021 21:23 UTC Invivyd, Inc. ADGI · Entity 721 ConversionSeries C Preferred Stock · Derivative 128,064 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-051296 · doc4.xml · derivative · entry 4

Gerngross Tillman U. · CIK 0001722061 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 640,320 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.

F2 · ownership.nature: These shares are held by Adimab, LLC (the "LLC"). The Reporting Person is an officer and member of the Board of Directors of the LLC and, as such, may be deemed to have shared voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 10, 2021 Filed Aug 12, 2021 21:23 UTC Invivyd, Inc. ADGI · Entity 721 ConversionSeries B Preferred Stock · Derivative 44,076 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-051296 · doc4.xml · derivative · entry 3

Gerngross Tillman U. · CIK 0001722061 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 220,380 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.

F2 · ownership.nature: These shares are held by Adimab, LLC (the "LLC"). The Reporting Person is an officer and member of the Board of Directors of the LLC and, as such, may be deemed to have shared voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 10, 2021 Filed Aug 12, 2021 21:23 UTC Invivyd, Inc. ADGI · Entity 721 ConversionSeries A Preferred Stock · Derivative 5,000,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-051296 · doc4.xml · derivative · entry 2

Gerngross Tillman U. · CIK 0001722061 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 25,000,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.

F2 · ownership.nature: These shares are held by Adimab, LLC (the "LLC"). The Reporting Person is an officer and member of the Board of Directors of the LLC and, as such, may be deemed to have shared voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 10, 2021 Filed Aug 12, 2021 21:23 UTC Invivyd, Inc. ADGI · Entity 721 ConversionCommon Stock 25,860,700 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-051296 · doc4.xml · nonDerivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 27,845,995

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.

F2 · ownership.nature: These shares are held by Adimab, LLC (the "LLC"). The Reporting Person is an officer and member of the Board of Directors of the LLC and, as such, may be deemed to have shared voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
June 17, 2021 Filed Jun 22, 2021 16:39 UTC Alector, Inc. ALEC · Entity 6051 GrantStock Option (right to buy) · Derivative 25,709 $0.00 Strike: $21.37 $0.00
Disclosure

SEC source: 0001209191-21-042410 · doc4.xml · derivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,709

Underlying: Common Stock · 25,709 shares

Expires 2031-06-17

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2021 and vest in full on the earlier of the date of the Issuer's next annual meeting of stockholders or June 17, 2022.

Read SEC document
May 11, 2020 Filed May 13, 2020 19:08 UTC Alector, Inc. ALEC · Entity 6051 GrantStock Option (right to buy) · Derivative 19,274 $0.00 Strike: $29.09 $0.00
Disclosure

SEC source: 0001209191-20-028986 · doc4.xml · derivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,274

Underlying: Common Stock · 19,274 shares

Expires 2030-05-11

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on June 11, 2020 and vest in full on the earlier of the date of the Issuer's next annual meeting of stockholders or May 11, 2021.

Read SEC document
May 10, 2019 Filed May 14, 2019 17:48 UTC Alector, Inc. ALEC · Entity 6051 GrantStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $20.05 $0.00
Disclosure

SEC source: 0001209191-19-029740 · doc4.xml · derivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2029-05-09

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest each month after the date of grant, provided that the option will vest in full on the earlier of (i) the twelve (12) month anniversary of the date of grant, or (ii) the date of the next regularly scheduled annual meeting of the Issuer's stockholders, in each case subject to the Reporting Person continuing to be a service provider through each applicable vesting date. The shares subject to the option will become fully vested and exercisable immediately prior to a change in control, subject to the Reporting Person continuing to be a service provider.

Read SEC document
February 11, 2019 Filed Feb 11, 2019 19:12 UTC Alector, Inc. ALEC · Entity 6051 ConversionSeries E Preferred Stock · Derivative 52,760 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-009119 · doc4.xml · derivative · entry 4

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 52,760 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each of the Series C Preferred Stock and Series E Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Each of the Series C Preferred Stock and Series E Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Each of the Series C Preferred Stock and Series E Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

Read SEC document
February 11, 2019 Filed Feb 11, 2019 19:12 UTC Alector, Inc. ALEC · Entity 6051 ConversionSeries C Preferred Stock · Derivative 374,532 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-009119 · doc4.xml · derivative · entry 3

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 374,532 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each of the Series C Preferred Stock and Series E Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

F1 · derivative.exercise_date: Each of the Series C Preferred Stock and Series E Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

F1 · derivative.expiration_date: Each of the Series C Preferred Stock and Series E Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

Read SEC document
February 11, 2019 Filed Feb 11, 2019 19:12 UTC Alector, Inc. ALEC · Entity 6051 ConversionCommon Stock 52,760 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-009119 · doc4.xml · nonDerivative · entry 2

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,608,610

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each of the Series C Preferred Stock and Series E Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

Read SEC document
February 11, 2019 Filed Feb 11, 2019 19:12 UTC Alector, Inc. ALEC · Entity 6051 ConversionCommon Stock 374,532 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-009119 · doc4.xml · nonDerivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,555,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each of the Series C Preferred Stock and Series E Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

Read SEC document
June 05, 2018 Filed Jun 7, 2018 16:19 UTC X4 Pharmaceuticals, Inc ASNS · Entity 5638 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $16.99 $0.00
Disclosure

SEC source: 0001209191-18-036337 · doc4.xml · derivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2028-06-04

F1 · derivative.exercise_date: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.

Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:32 UTC X4 Pharmaceuticals, Inc ASNS · Entity 5638 ConversionSeries D Convertible Preferred Stock · Derivative 308,099 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-027004 · doc4.xml · derivative · entry 3

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,272 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:32 UTC X4 Pharmaceuticals, Inc ASNS · Entity 5638 PurchaseCommon Stock 200,000 $10.00 $2,000,000.00
Disclosure

SEC source: 0000899243-17-027004 · doc4.xml · nonDerivative · entry 2

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 392,821

Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:32 UTC X4 Pharmaceuticals, Inc ASNS · Entity 5638 ConversionCommon Stock 90,272 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-17-027004 · doc4.xml · nonDerivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,821

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.

Read SEC document
November 15, 2017 Filed Dec 1, 2017 17:24 UTC X4 Pharmaceuticals, Inc ASNS · Entity 5638 GrantStock Option (right to buy) · Derivative 7,324 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0000899243-17-027831 · doc4.xml · derivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,324

Underlying: Common Stock · 7,324 shares

Expires 2027-11-14

F1 · security: Consists of an automatic stock option grant that was made on November 15, 2017, the date of the effectiveness of the registration statement for the issuer's initial public offering, under the issuer's director compensation program.

F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.

Read SEC document
November 15, 2017 Filed Mar 5, 2018 16:59 UTC Amendment X4 Pharmaceuticals, Inc ASNS · Entity 5638 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0001209191-18-016569 · doc4a.xml · derivative · entry 1

Gerngross Tillman U. · CIK 0001722061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2027-11-14

F1 · shares: Consists of an automatic stock option grant that was made pursuant to the issuer's director compensation policy on November 15, 2017, the date of effectiveness of the registration statement for the issuer's initial public offering. Under the terms of the policy, the Reporting Person received an option to purchase 25,000 shares. Due to a clerical error, the original Form 4 filed on December 1, 2017 erroneously reported an option grant of 7,324 shares. This Amendment to Form 4 is filed solely to correct the share number.

F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.